---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056994"
form_type: "8-K"
ticker: null
cik: "0001850079"
company_name: "Telesis Bio Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:04:05.923944+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Telesis Bio Q1 revenue $3.4M down 46% YoY; net loss $8.6M improves from $11.1M

## Summary
- Revenue $3.4M vs $6.3M YoY; product revenue fell $1.7M and collaboration revenue $1.0M.
- Net loss $8.6M ($5.52 EPS) vs $11.1M ($6.75 EPS) YoY; operating expenses cut 31% to $10.0M.
- Cash, equivalents and investments $15.7M at March 31, 2024; long-term notes payable $5.2M.
- Strategic focus on Gibson SOLA and BioXp mRNA; 40% of new instrument buyers cite mRNA workflow.
- Pfizer collaboration progressing; no forward-looking guidance provided.

## SEC filing metadata
- accession: 0000950170-24-056994
- form_type: 8-K
- cik: 0001850079
- company_name: Telesis Bio Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850079/000095017024056994/0000950170-24-056994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850079/000095017024056994/tbio-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056994
- JSON: https://secwatch.observer/filing/0000950170-24-056994.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056994.txt

## Key facts
- Earnings Releases
  Telesis Bio Inc. reported the quarter ended March 31, 2024 results: revenue $3.4 million, net income $8.6 million, EPS $5.52.
  - Period: the quarter ended March 31, 2024
  - Revenue: $3.4 million
  - Net income: $8.6 million
  - EPS: $5.52
  - Result: reported results
  source text: strategy, is reduced 31% from the first quarter of the prior year. Summary of First Quarter 2024 Financial Results Revenue for the three months ended March 31, 2024 was $3.4 million compared to $6.3 million for the three months ended March 31, 2023. The decrease of $2.9 million was attributable to a decrease in product revenue of $1.7 million, a decrease in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000095017024056994/0000950170-24-056994-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.